Development of a nomogram incorporating serum C-reactive protein level to predict overall survival of patients with advanced urothelial carcinoma and its evaluation by decision curve analysis
暂无分享,去创建一个
M. Yokoyama | J. Ishioka | Y. Matsuoka | Y. Fujii | N. Numao | H. Masuda | M. Sakura | S. Kawakami | K. Saito | F. Koga | K. Kihara
[1] T. Todenhöfer,et al. Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C‐reactive protein and standard pathological risk factors: the TNR‐C score , 2011, BJU international.
[2] Kazutaka Saito,et al. C-reactive protein as a biomarker for urological cancers , 2011, Nature Reviews Urology.
[3] K. Kihara,et al. A novel repeat biopsy nomogram based on three-dimensional extended biopsy. , 2011, Urology.
[4] M. Kattan,et al. Risk grouping versus risk continuum in patients with clinically localized prostate cancer: a taxometric test. , 2010, The Journal of urology.
[5] S. Culine,et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] A. Haese*,et al. Head-to-head comparison of the three most commonly used preoperative models for prediction of biochemical recurrence after radical prostatectomy. , 2010, European urology.
[7] Andrew J Vickers,et al. Traditional statistical methods for evaluating prediction models are uninformative as to clinical value: towards a decision analytic framework. , 2010, Seminars in oncology.
[8] 田所 学. Prognostic impact of postoperative C-reactive protein level in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy , 2010 .
[9] D. McMillan,et al. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. , 2010, Future oncology.
[10] M. Nieto,et al. Inflammation and EMT: an alliance towards organ fibrosis and cancer progression , 2009, EMBO molecular medicine.
[11] M. Agerbaek,et al. Predictive factors for response and prognostic factors for long-term survival in consecutive, single institution patients with locally advanced and/or metastatic transitional cell carcinoma following cisplatin-based chemotherapy , 2009, Acta oncologica.
[12] 飯村 康正. Development and external validation of a new outcome prediction model for patients with clear cell renal cell carcinoma treated with nephrectomy based on preoperative serum C-reactive protein and TNM classification : the TNM-C score , 2009 .
[13] Elena B. Elkin,et al. Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers , 2008, BMC Medical Informatics Decis. Mak..
[14] K. Kihara,et al. Prognostic impact of postoperative C-reactive protein level in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy. , 2008, The Journal of urology.
[15] Shahrokh F. Shariat,et al. Comparison of Nomograms With Other Methods for Predicting Outcomes in Prostate Cancer: A Critical Analysis of the Literature , 2008, Clinical Cancer Research.
[16] K. Kihara,et al. C‐reactive protein level predicts prognosis in patients with muscle‐invasive bladder cancer treated with chemoradiotherapy , 2008, BJU international.
[17] P. Malmström. WHY HAS THE SURVIVAL OF PATIENTS WITH BLADDER CANCER NOT IMPROVED? , 2008, BJU international.
[18] K. Kihara,et al. The impact of preoperative serum C‐reactive protein on the prognosis of patients with upper urinary tract urothelial carcinoma treated surgically , 2007, BJU international.
[19] D. McMillan,et al. Evaluation of an inflammation‐based prognostic score in patients with metastatic renal cancer , 2006, Cancer.
[20] E. Elkin,et al. Decision Curve Analysis: A Novel Method for Evaluating Prediction Models , 2006, Medical decision making : an international journal of the Society for Medical Decision Making.
[21] Sergio Ricci,et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] M. Mazumdar,et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] C. C. Chen,et al. The bootstrap and identification of prognostic factors via Cox's proportional hazards regression model. , 1985, Statistics in medicine.
[24] F. Harrell,et al. Evaluating the yield of medical tests. , 1982, JAMA.